Follow-up on a Novel Adeno-Associated Virus (AAV) Gene Therapy (FLT180a) Achieving Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

Conference Coverage

Efficacy and Safety of Etranacogene Dezaparvovec in Adults With Severe or Moderate-severe Hemophilia B: First Data From the Phase 3 Hope-B Gene Therapy Trial

Conference Coverage

Characterisation of Adeno-Associated Virus Vector Persistence After Long-Term Follow-up in the Haemophilia A Dog Model

Conference Coverage

Long-term Outcomes: Durability and Safety

Interactive Webinars

Key Considerations: Advances in Gene Therapy for Hemophilia ENDURING

Interactive Webinars

EAHAD Gene Therapy Working Group

Podcasts

ISTH Gene Therapy for Hemophilia Initiative and the Role of EAHAD

Podcasts

History of EAHAD and the Upcoming Congress

Podcasts

Hemophilia Gene Therapy: Expectations for Reliability and Accessibility

Podcasts

First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A – BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII

Conference Coverage

Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults With Severe or Moderate-Severe Hemophilia B: Two Year Data From a Phase 2b Trial

Conference Coverage

First Data From the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults With Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing

Conference Coverage

AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for Up to 5 Years

Conference Coverage

The World Federation of Hemophilia Gene Therapy Registry

Conference Coverage

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults With Severe Hemophilia

Conference Coverage

Latest Advances in Gene Therapy for Hemophilia in Portuguese

Podcasts

Obstacles and Opportunities

Interactive Webinars

Key Considerations: Advances in Gene Therapy for Hemophilia

Interactive Webinars

Stepping Into the Future: Hemophilia Gene Therapy Clinical Trial Updates

Interactive Webinars

Patient Support, Patient Counseling, and Monitoring

Interactive Webinars

Gene Therapy for FVIII

Interactive Webinars

Learning from Clinical Trials and Preparing for Clinical Practice

Interactive Webinars

Frequency, Location and Nature of AAV Vector Insertions After Long-term Follow-up of FVIII Transgene Delivery in a Hemophilia A Dog Model

Conference Coverage

A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

Conference Coverage

Subcategories

Monthly Roundup

Interactive Webinars

Podcasts

Conference Coverage

Highlights From the 17th Annual Congress of EAHAD

Highlights From the 65th ASH Annual Meeting and Exposition

Highlights From the ESGCT 30th Annual Congress

Highlights From the 31st Congress of ISTH

Highlights From the 32nd Congress of ISTH

Gene Therapy Illustrated Clinical Trials

Microlearning

Back To Top
Image

About

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL